human hemin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
human hemin: clinical details
Prescribing considerations
- Confirm an acute hepatic porphyria attack using the clinical context and quantitative urinary ALA and porphobilinogen.
- Seek specialist porphyria advice and address triggers, fasting and inadequate carbohydrate intake.
- Use a large forearm or central vein, an inline filter and appropriate flushing to reduce administration-related harm.
- Record the product name and batch number because it is derived from human blood.
- Do not use routinely for attack prevention; repeated exposure carries an iron-overload risk.
Contraindications and cautions
- Hypersensitivity to human hemin or any excipient.
- Consider the ethanol content carefully in pregnancy, childhood, liver disease, alcohol dependence, epilepsy, or brain injury or disease.
Monitoring
- Cardiovascular and neurological manifestations of the acute attack
- Infusion site for phlebitis, thrombosis, extravasation and tissue injury
- Serum ferritin and body iron stores after repeated infusions
Clinical pharmacology
Exogenous hemin restores hepatic haem feedback, suppressing delta-aminolaevulinic acid synthase and reducing production of porphyrins, ALA and porphobilinogen.
Formulation and product differences
- The selected product is a dark, human blood-derived concentrate containing arginine, ethanol, propylene glycol and water for injections.
- It requires refrigerated, light-protected storage and immediate dilution in sodium chloride solution; a glass container is specified because degradation is faster in PVC.
- The prepared infusion should be used promptly and must not be mixed with medicines other than the specified diluent.
human hemin preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 25 mg/mL
human hemin interactions
The porphyria team should review all prescribed, over-the-counter and hormonal medicines.
Oestrogens
They may trigger or worsen attacks, while treatment may reduce their systemic exposure.
Barbiturates
They may precipitate attacks, and their systemic exposure may be reduced during treatment.
Corticosteroids
Some may worsen porphyria, and increased metabolism during treatment may lower their systemic exposure.
Other cytochrome P450 substrates
Their metabolism may increase during treatment, potentially reducing exposure and requiring clinical review.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.